Lunit

328130.KQ

33.00 USD

0.33

+1.01%

Overview

Last close

33.00 usd

Market cap

956.72M usd

52 week high

58.23 usd

52 week low

23.39 usd

Target price

35.49 usd

Valuation

P/E

N/A

Forward P/E

N/A

Price/Sales

19.3537

Price/Book Value

7.6767

Enterprise Value

970.97M usd

EV/Revenue

19.642

EV/EBITDA

-45.3273

Key financials

Revenue TTM

49.43M usd

Gross Profit TTM

49.43M usd

EBITDA TTM

-48.18M usd

Earnings per Share

N/A usd

Dividend

N/A usd

Total assets

280.95M usd

Net debt

9.53M usd

About

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such as Epidermal Growth Factor Receptor mutations. Lunit Inc. was founded in 2013 and is based in Seoul, South Korea.